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INTRODUCTION
Pelvic	radiotherapy	is	frequently	indicated	in	the	treatment	
of	patients	with	gynecologic	cancers	[1,2].	However,	pelvic	
radiotherapy	can	induce	a	variety	of	complications,	includ-
ing	nausea,	vomiting,	anorexia,	and	diarrhea,	and	ultimately	
decreases	patients’	quality	of	life	(QoL)	[3-5].	In	addition	to	
increasing	life	expectancy	in	cancer	patients,	interventional	
strategies	for	minimizing	adverse	side	effects	and	improving	
patients’	QoL	should	be	considered	an	urgent	necessity.	To	
achieve	these	goals,	investigations	should	be	focused	on	as-
sessing	the	role	of	certain	specific	factors	that	might	influence	
such	symptoms.	
There	are	some	possible	biologic	markers,	the	levels	of	which	
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Objective:	We	conducted	a	pilot	study	to	evaluate	the	effects	of	pelvic	radiotherapy	on	biologic	markers	of	oxidative	stress	
and	plasma	endotoxin	levels,	and	to	assess	the	relationship	between	the	changes	of	such	factors	and	radiotherapy-related	
complications.
Methods:	Twelve	gynecologic	cancer	patients	who	were	treated	via	pelvic	radiotherapy	with	or	without	concurrent	
chemotherapy	were	enrolled	in	this	study.	Biologic	markers	of	oxidative	stress,	such	as	glutathione	(GSH)	and	oxidized	
glutathione	(GSSG),	as	well	as	endotoxin	levels,	were	measured	weekly	during	treatment.	Subjective	symptoms	were	assessed	
using	the	Korean	version	of	the		EORTC	QLQ-C30	at	the	baseline	and	on	the	5th	week	of	radiotherapy.	
Results:	No	changes	were	noted	in	the	level	of	GSH	in	whole	blood,	but	the	GSH/GSSG	ratio	was	reduced	dramatically	after	the	
initiation	of	radiotherapy.	The	mean	plasma	endotoxin	for	all	patients	tended	to	increase	and	persisted	during	radiotherapy,	and	
the	number	of	patients	who	evidenced	clinically	significant	endotoxin	levels	(defined	as	>0.005	EU/mL)	also	increased.	Nausea/
vomiting	and	diarrhea	were	significantly	changed	(p=0.019	and	p<0.001,	respectively).	A	significant	relationship	was	noted	to	
exist	between	the	changes	in	the	endotoxin	level	and	nausea/vomiting	(p=0.001).	However,	such	symptoms	did	not	correlate	
with	the	changes	of	oxidative	stress	markers.
Conclusion: Pelvic	radiotherapy	oxidized	the	GSH	redox	system	and	increased	plasma	endotoxin.	Further	investigations	
containing	interventional	and	longitudinal	studies	will	be	required	to	assess	the	effects	of	the	changes	in	oxidative	stress	
markers	and	endotoxin	on	radiotherapy-related	adverse	events.
Keywords:	Adverse	effects,	Endotoxins,	Oxidative	stress,	Radiotherapy
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might	be	changeable	during	pelvic	radiotherapy.	First,	as	the	
main	therapeutic	mechanism	of	radiation	is	oxidative	damage	
to	cancer	cells,	it	can	be	assumed	that	some	changes	occur	
in	the	levels	of	oxidative	stress	markers	during	radiotherapy,	
resulting	in	the	upregulation	of	inflammatory	cytokines,	ad-
ditional	signaling,	and	the	amplification	of	inflammatory	
pathways.	Endotoxin	is	another	possible	factor	that	might	
be	correlated	closely	with	intestinal	toxicities.	Endotoxin	can	
enter	the	systemic	circulation	due	to	intestinal	barrier	break-
down	by	pelvic	radiotherapy,	and	the	high	incidence	of	endo-
toxin	in	the	blood	may	be	associated	with	nausea,	vomiting,	
abdominal	pain,	anorexia,	and	diarrhea,	the	symptoms	most	
frequently	induced	by	pelvic	radiotherapy	[6,7].	
Although	some	markers	of	oxidative	stress	and	endotoxins	
have	been	under	investigation	for	the	evaluation	of	their	rela-
tionship	with	various	diseases,	limited	information	is	available	
regarding	the	changes	in	the	levels	of	oxidative	stress	markers	
and	endotoxins	during	pelvic	radiotherapy,	and	their	correla-
tions	with	radiotherapy-related	adverse	events	[8-10].	
The	principal	objective	of	this	study	was	to	determine	the	
influence	of	pelvic	radiotherapy	with	or	without	concurrent	
chemotherapy	on	oxidative	stress	and	plasma	endotoxins,	
and	to	assess	their	correlation	with	radiotherapy-related	ad-
verse	events.
MATERIALS AND METHODS
1. Patients and treatment 
We	conducted	a	prospective,	single-center	pilot	study	at	
Seoul	National	University	Hospital.	A	total	of	12	patients	with	
endometrial	(n=4)	or	cervical	(n=8)	cancer	voluntarily	enrolled	
in	this	pilot	study	between	October	2010	and	March	2011;	the	
study	was	approved	and	overseen	by	the	Institutional	Review	
Board	of	Seoul	National	University	Hospital	in	Korea,	and	all	
patients	provided	written	informed	consent	before	participat-
ing	in	the	study.	Characteristics	of	patients,	including	their	
treatments	are	summarized	in	Table	1.
All	patients	underwent	radical	hysterectomy	with	pelvic	
lymph	node	dissection,	and	adjuvant	radiotherapy	with	or	
without	chemotherapy	was	delivered	within	2-4	weeks	of	sur-
gery.	Adjuvant	radiotherapy	was	delivered	to	the	whole	pelvis	
at	1.8	Gy	per	fraction	once	daily,	5	days	per	week.	The	median	
dose	to	the	whole	pelvis	was	50.4	Gy.	The	details	of	the	radia-
tion	technique	were	described	in	a	previous	publication	[11].	
Among	12	patients,	nine	received	adjuvant	chemotherapy	
with	radiotherapy.	Overnight-fasted	venous	blood	at	baseline,	
1st,	2nd,	3rd,	4th	and	5th	weeks	of	radiotherapy	were	col-
lected	in	heparinized	tubes	and	immediately	processed.
2. Measurement of total glutathione (GSH) and oxidized 
GSH (GSSG)
The	total	GSH	(reduced	and	oxidized)	and	GSSG	levels	were	
determined	using	a	Glutathione	Assay	kit	(NWK-GSH01,	North-
west	Life	Science	Specialties,	Vancouver,	WA,	Canada)	based	
on	the	kinetics	of	the	GSH	recycling	pathway	by	GSH	reduc-
tase	[12].	The	heparinized	whole	blood	was	mixed	with	5%	
metaphosphoric	acid	(Sigma,	St,	Louis,	MO,	USA),	vortexed,	
and	centrifuged	for	10	minutes	at	10,000×g.	The	superna-
tants	were	collected	and	assayed	in	accordance	with	the	
manufacturer’s	instructions.	In	the	case	of	GSSG	determina-
tion,	deproteinized	supernatants	were	further	incubated	with	
Table 1. Patients’ characteristics 
Patient no. Diagnosis FIGO stage Age Radiotherapy dose (Gy) Chemotherapy
1 Cervical cancer IB1 46 50.4 Fluorouracil+cisplatin
2 Cervical cancer IB1 35 50.4 Weekly cisplatin
3 Cervical cancer  IB1 60 50.4 Weekly cisplatin
4 Cervical cancer  IB1 51 50.4 Paclitaxel+carboplatin
5 Cervical cancer IB1 49 50.4 Paclitaxel+carboplatin
6 Cervical Cancer IIA 45 50.4 Etoposide+cisplatin
7 Cervical cancer  IIB 64 50.4 Paclitaxel+carboplatin
8 Cervical cancer  IIB 55 59.4 Paclitaxel+carboplatin
9 Endometrial cancer IA 56 50.4 Not done
10 Endometrial cancer  IA 63 50.4 Not done
11 Endometrial cancer IB 50 50.4 Not done
12 Endometrial cancer IIIC 38 50.4 Paclitaxel+carboplatinOxidative stress and plasma endotoxin
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4-vivinylpyridine,	a	thiol-blocking	agent,	for	60	min	at	room	
temperature	in	order	to	scavenge	free	GSH	in	the	sample.	
Each	of	the	supernatants	was	mixed	with	5-5’-dithiobis	(2-ni-
trobenzoic	acid;	DTNB),	-nicotinamide	adenine	dinucleotide	
phosphate	(NADPH)	and	GSH	reductase.	Samples	were	incu-
bated	in	darkness	for	3	minutes	and	then	the	total	GSH	was	
quantified	after	kinetic	spectrophotometric	analysis	at	412	nm	
using	a	Spectra	Max	180	(Molecular	Devices,	Sunnyvale,	CA,	
USA).	GSH	and	GSSG	concentrations	were	calculated	from	the	
appropriate	calibration	curves.	Free	GSH	was	obtained	by	sub-
tracting	the	concentration	of	GSSG	from	total	GSH.	
3. Measurement of plasma endotoxin
Endotoxins	in	plasma	was	measured	using	a	Limulus	amoe-
bocyte	lysate	(LAL)	assay	kit	(Diatech,	Seoul,	Korea)	using	the	
kinetic	turbidimetric	method.	We	took	a	great	deal	of	care	to	
prevent	possible	contamination	with	exogenous	endotoxins	
or	its	adsorption	to	the	test	materials.	Diluted	plasma	sample	
with	BD100	buffer	was	heat-inactivated	for	10	minutes	at	75
oC	
and	then	cooled	on	ice.	Samples	and	appropriate	standards	
from	known	concentrations	of	LAL	reagent	were	incubated	
for	1	hour	at	37
oC.	OD	at	395	nm	was	continuously	read	at	
30	second	intervals	with	an	Endo-Check	Analyzer	I	(Diatech).	
Endotoxin	levels	were	calculated	from	kinetic	graphs,	and	the	
cutoff	value	was	set	to	0.005	EU/mL.	
4. EORTC QLQ-C30 questionnaire
The	QoL	change	in	the	course	of	treatment	was	determined	
at	the	baseline	and	the	5th	week	of	radiotherapy	using	the	
Korean	version	of	the	cancer-specific	module	of	the	European	
Organization	for	Research	and	Treatment	of	Cancer	(EORTC)	
QLQ	C-30	questionnaire	[13].	The	Korean	EORTC	QLQ	C-30	
was	developed	by	EORTC	using	a	rigorous	translation	and	
back	translation	process,	and	demonstrated	as	a	valid	instru-
ment	for	evaluating	Korean-speaking	patients	with	cancer.	
Korean	version	of	EORTC	QLQ	C-30	have	the	questionnaire	
incorporating	five	functional	scales	(physical,	role,	cognitive,	
emotional,	and	social),	three	symptom	scales	(fatigue,	pain,	
and	nausea	and	vomiting),	a	global	health	and	QoL	scale,	and	
single	items	for	the	assessment	of	additional	symptoms	com-
monly	reported	by	cancer	patients	(e.g.,	dyspnea,	appetite	
loss,	sleep	disturbance,	constipation,	and	diarrhea),	as	well	as	
the	perceived	financial	impact	of	the	disease	and	treatment.	
QLQ-C30	adopted	a	self-rating	scale	for	patient	completion	
at	baseline	and	the	5th	week	of	treatment.	All	scale	and	item	
scores	were	transformed	into	a	scale	of	0-100.	High	scores	
for	a	functional	scale	and	global	health	status	reflect	a	high	
and	healthy	level	of	functioning	and	a	high	QoL,	respectively.	
However,	a	high	score	for	a	symptom	scale/item	reflects	a	
high	level	of	symptoms	and	problems.
5. Statistical analysis
All	data	are	expressed	as	means±standard	error,	and	we	used	
Sigma	Stat	software	(Systat	Software	Inc.,	San	Jose,	CA,	USA).	
Weekly	measured	data	were	compared	to	baseline	values	by	
using	the	paired	t-test.	We	used	the	paired	t-test	just	to	ascer-
tain	which	session	shows	the	significant	change	com	 pared	
to	the	baseline.	Paired	t-test	was	also	used	in	comparing	the	
changes	in	symptoms	between	at	baseline	and	at	final	treat-
ment.	The	relationship	between	biologic	markers	and	patient’s	
symptoms	was	analyzed	via	Kendall	tau.	The	p-values	less	than	
0.05	were	considered	statistically	significantly	different.
RESULTS
1. GSH, GSSG, and GSH/GSSG ratio
The	mean	basal	blood	GSH	for	12	patients	was	894.6±90.5	
M	(range,	549.0	to	1,408.2	M)	and	no	significant	changes	were	
noted	in	the	level	of	GSH	during	radiotherapy.	The	mean	value	
of	GSSG,	which	is	the	oxidized	form	of	GSH	and	reflects	the	
extent	of	oxidative	stress,	was	27.2±10.8	M	at	baseline.	Dur-
ing	the	course	of	radiotherapy,	GSSG	was	significantly	high	
at	the	2nd	(85.7±17.2,	p=0.01),	3rd	(72.6±13.7,	p=0.018)	and	
4th	(76.6±16.3,	p=0.01)	weeks	of	radiotherapy,	and	returned	
to	basal	levels	at	the	5th	week	of	treatment	(27.4±34.4).	The	
GSH/GSSG	ratio	after	treatment	was	reduced	dramatically	at	
the	2nd	(12.9±5.6,	p=0.026),	3rd	(11.5±3.6,	p=0.045),	and	4th	
(14.6±5.7,	p=0.045)	weeks	of	radiotherapy	(Fig.	1).	Although	it	
was	not	statistically	significantly	different,	the	GSH/GSSG	ratio	
after	the	5th	week	of	treatment	(27.6±3.6)	never	fully	recov-
ered	to	baseline	(46.1±12.3).
Fig. 1. Glutathione (GSH)/oxidized glutathione (GSSG) ratio during 
radiotherapy. GSH/GSSG ratio=GSH/GSSG.Hak Jae Kim, et al.
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2. Endotoxin 
The	cutoff	value	of	plasma	endotoxin	was	set	at	0.005	EU/
mL.	The	mean	value	of	plasma	endotoxin	for	12	patients	was	
0.0045±0.0012	EU/mL	and	2	out	of	12	patients	(16.7%)	evi-
denced	positive	values	prior	to	treatment,	which	is	defined	as	
values	in	excess	of	the	cutoff	value.	The	mean	endotoxin	level	
for	all	patients	evidenced	an	increasing	tendency	and	persist-
ed	during	radiotherapy	(Fig.	2A).	Additionally,	the	number	of	
patients	with	greater	than	the	cutoff	value	of	endotoxin	was	
increased	at	the	end	of	radiotherapy	(8/12)	(Fig.	2B).
Fig. 2. Blood endotoxin level (A) and positive rate (B) in patient subjects during radiotherapy. Endotoxin was expressed as mean±standard 
error. Endotoxin level between baseline and at 5th week of treatment was statistically significant (p<0.05) according to the results of the t-test.
Table 2. Result of Korean version of  EORTC QLQ-C30 questionnaire at baseline and 5th week of radiotherapy
EORTC QLQ-C30 Baseline 5th week % change of baseline p-value*
Functioning scales 
  Global health status 54.17±4.81 37.5±4.54 -30.8 0.049
  Physical functioning 75.56±3.99 66.11±4.96 -12.5 0.164
  Role functioning 68.06±8.46 47.22±8.94 -30.6 0.111
  Emotional functioning 72.92±3.74 71.53±5.51 -1.9 0.833
  Cognitive functioning 76.39±4.98 68.06±5.27 -10.9 0.252
  Social functioning 68.06±7.28 56.94±8.82 -16.3 0.362
Symptom scales
†
  Fatigue 40.74±4.06 51.85±8.22 27.3 0.437
  Nausea/vomiting 8.33±3.31 30.56±8.18 266.7 0.019
  Pain 22.22±4.72 34.72±9.08 56.3 0.234
Single-item scales
†
  Dyspnea  22.22±6.22 33.33±9.08 50.0 0.328
  Insomnia 25.0±8.41 47.22±8.99 88.9 0.089
  Appetite loss 16.67±5.03 47.22±10.86 183.3 0.045
  Constipation 8.33±4.49 11.11±6.49 33.3 0.939
  Diarrhea 5.56±3.89 52.78±9.97 850.0 <0.001
  Financial difficulties 22.22±7.57 36.11±11.24 62.5 0.440
Values are presented as mean±standard error. 
EORTC, European Organization for Research and Treatment of Cancer; QLQ, quality of life questionnaire.
*p-value was determined by paired t-test between baseline and final treatment. 
†Scores range from 0 to 100, with a higher score representing 
a greater degree of symptoms. Oxidative stress and plasma endotoxin
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3. Patients’ QoL 
The	mean	patient	scores	are	provided	in	Table	2.	In	func-
tioning	scales	of	the	Korean	version	of	EORTC	QLQ-C30,	the	
global	health	status	item	(54.17±4.81)	was	the	lowest	score	
in	patient	subjects	prior	to	radiotherapy.	Among	symptom	
scales	and	single-item	scales,	the	fatigue	score	showed	the	
highest	value	(40.74±4.06)	at	pre-radiotherapy.	In	paired	t-
test	analysis	between	different	items	at	baseline,	radiotherapy	
induced	a	significant	change	in	the	score	of	global	health	
status	(p=0.049)	in	functioning	scales,	and	nausea/vomit-
ing	apparently	worsened	(p=0.019)	in	the	symptom	scales.	
When	compared	to	the	baseline	in	single-item	scales,	scores	
for	appetite	loss	and	diarrhea	were	increased	significantly,	by	
183.3%	(p=0.045)	and	850%	(p<0.001),	respectively.	
4. Correlation between biologic markers and subjective 
symptoms
Significant	symptom	changes	in	nausea/vomiting	and	diar-
rhea	were	observed	pre-	and	post-radiotherapy	in	this	study.	
Such	symptoms	evidenced	no	correlation	with	biologic	mark-
ers	of	oxidative	stress,	including	GSH,	GSSG,	and	GSH/GSSG.	
However,	the	change	in	the	level	of	endotoxin	was	associated	
significantly	with	nausea/vomiting	(p=0.001)	(Fig.	3A),	but	not	
with	diarrhea	(p=0.196)	(Fig.	3B).
DISCUSSION
This	study	aimed	to	assess	the	influence	of	pelvic	radio-
therapy	on	biologic	markers	of	oxidative	stress	and	plasma	
endotoxin	levels,	and	to	assess	the	relationship	between	the	
changes	of	such	factors	and	radiotherapy-related	adverse	
events.	A	few	previous	studies	have	implied	that	systemic	oxi-
dative	burden	may	increase	as	the	result	of	radiotherapy	with	
or	without	concomitant	chemotherapy	[14-19].	We	measured	
blood	GSH	and	GSSH,	which	may	serve	as	a	good	indicator	
of	the	oxidative	stress	of	both	the	body	and	the	tumor	[20].	
This	study	was	unable	to	detect	any	significant	changes	in	the	
levels	of	GSH	during	radiotherapy.	However,	unlike	what	was	
found	with	GSH,	GSSG	accumulated	and	GSH/GSSG	was	re-
duced	under	increased	oxidative	stress	conditions.	Although	
GSH	is	a	ubiquitous	cellular	antioxidant	and	a	highly	sensitive	
indicator	of	cell	functionality	and	viability	under	physiologi-
cal	and	pathological	conditions,	GSH	is	known	to	be	recycled	
back	by	GSH	reductase	[21].	Transient	reduction	and	imme-
diate	recovery	of	GSH	levels	may	not	be	accurate	indicators	
of	oxidative	stress	status.	Therefore,	according	to	this	study,	
the	value	of	GSSG	and	the	ratio	of	GSH/GSSG	may	prove	to	
be	more	useful	indicators	of	oxidative	stress	status	than	that	
of	GSH	in	patients	treated	with	radiotherapy.	Nevertheless,	
it	is	not	clear	why	GSSG	level	returned	to	basal	levels	at	the	
5th	week	of	treatment.	It	might	be	partly	explained	by	the	
hypothesis	that	GSSG	is	known	to	be	reduced	back	to	GSH	
by	GSH	reductase	using	NADPH.	If	reactive	oxygen	species	
increases,	it	oxidizes	our	body	and	simultaneously	induces	
multiple	antioxidative	systems,	which	might	compensate	the	
oxidative	burden	and	recycle	the	GSH	system.
We	were	unable	to	come	to	any	clear	conclusions	regard-
ing	the	correlation	between	changes	in	GSH/GSSG	ratio	and	
subjective	symptoms.	The	tendency	to	return	to	basal	levels	
Fig. 3. The change in the level of endotoxin was associated significantly with nausea/vomiting (p=0.001; (A) arrow head: 3 patients overlapped), 
but not with diarrhea (p=0.196; (B) arrow: 2 patients overlapped). Endotoxin final-baseline, difference in the endotoxin values between final 
and baseline week; Nausea and vomiting severity, difference in the severity of nausea and vomiting between final and baseline week; Diarrhea 
severity, difference in the severity of diarrhea between final and baseline week.Hak Jae Kim, et al.
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at	the	5th	week	made	it	quite	difficult	to	analyze	the	relevant	
relationships,	considering	that	the	severity	of	radiotherapy-
related	adverse	effects	generally	increases	from	the	beginning	
to	the	end	of	radiotherapy.	Additionally,	the	degree	and	pat-
tern	of	changes	in	GSH/GSSG	ratio	differed	among	individual	
cases.	The	GSH/GSSG	ratio	was	observed	to	recover	at	the	
middle	or	final	stage	in	some	patients,	while	others	did	not	re-
cover,	evidencing	sustained	oxidations	of	the	GSH-GSSG	sys-
tem.	Therefore,	it	remains	to	be	clearly	determined	whether	
oxidative	stress,	which	was	determined	as	a	GSH/GSSG	ratio	
in	our	study,	is	a	simply	transient	therapeutic	toxicity	associ-
ated	with	radiotherapy,	or	if	this	impairment	of	redox	balance	
serves	as	an	early	indicator	in	the	development	of	treatment-
related	adverse	events	[22].	Diminishing	oxidative	stress	has	
been	recognized	as	an	important	therapeutic	approach,	and	
thus	antioxidants	are	frequently	taken	in	conjunction	with	
conventional	anticancer	treatment	to	reduce	a	variety	of	com-
plications.	Some	investigators	who	are	concerned	about	the	
role	of	oxidative	stress	in	the	development	of	various	compli-
cations	have	attempted	to	manage	this	oxidative	stress	with	a	
variety	of	antioxidant	interventions	during	the	administration	
of	cancer	therapies	[21,23].	However,	opponents	insist	that	
antioxidant	intervention	may	reduce	the	therapeutic	effects	of	
anticancer	therapies,	because	the	anti-cancer	effects	of	che-
motherapy	or	radiotherapy	is	substantially	mediated	by	oxi-
dative	stress	via	the	generation	of	free	radicals,	and	thus	the	
use	of	antioxidant	may	occasionally	interfere	with	the	effects	
of	anticancer	treatment.	Until	now,	there	has	been	a	decided	
lack	of	evidence	not	only	with	regard	to	the	clinical	efficacy	
of	antioxidants,	but	also	the	diminishing	effect	against	anti-
cancer	therapy.	In	particular,	very	little	information	is	currently	
available	regarding	oxidative	stress	and	the	efficacy	of	antioxi-
dant	intervention	from	a	radiotherapy	perspective.	Therefore,	
further	investigations	into	the	clinical	significance	of	oxidative	
stress	will	be	necessary	to	clearly	assess	the	feasibility	of	the	
clinical	use	of	antioxidative	intervention.	
Endotoxins,	another	biologic	marker,	was	measured	during	
pelvic	radiotherapy.	Pelvic	radiotherapy	can	damage	intestinal	
mucosal	cells,	by	which	endotoxin	can	enter	into	the	blood	
via	the	degradation	of	the	gut	permeability	barrier.	Endotoxins	
are	a	component	of	the	outer	membrane	of	gram-negative	
bacteria	and	is	known	to	lead	to	innate	immune	system	when	
administered	to	rodents	or	humans	[24].	In	this	study,	endo-
toxins	evidenced	a	tendency	to	increase,	and	the	number	of	
patients	with	a	positive	endotoxin	value	during	radiotherapy	
tended	to	increase	during	radiotherapy.	Among	subjective	
symptoms	determined	over	the	course	of	treatment,	nausea/
vomiting	and	diarrhea	were	observed	at	dramatic	levels	at	
the	end	of	radiotherapy.	A	close	correlation	between	nausea/
vomiting	and	the	change	in	the	plasma	endotoxin	level	was	
observed.	Although	this	result	does	not	necessarily	mean	that	
the	endotoxin	directly	induces	nausea/vomiting	or	diarrhea,	
endotoxin	might	be	one	of	the	critical	factors	that	induce	
radiotherapy-related	adverse	events.	In	the	rat	model,	the	lev-
els	of	endotoxin	increased	significantly	in	irradiated	rats	when	
compared	to	healthy	controls,	and	radiation	enteritis	was	re-
lated	closely	to	bacteremia	and	endotoxinemia.	High	doses	of	
endotoxin	(>1	ng/kg)	administration	can	induce	flu-like	symp-
toms,	and	low	doses	of	endotoxin	administration	(<1	ng/kg)	
in	human	subjects	may	induce	inflammatory	processes,	which	
result	in	fatigue,	reduced	appetite,	and	cognitive	impairments	
[25].	Also,	a	probiotic	interventional	study	by	Seal	et	al.	[25]	
reported	that	the	endotoxin	levels	increased	significantly	in	
irradiated	rats	and	probiotics	reduce	radiotherapy-induced	
enteritis	along	with	a	reduction	in	endotoxin	levels.	Therefore,	
further	investigations	to	enroll	more	patients	and	interven-
tional	studies	with	probiotics,	which	are	known	to	reduce	en-
dotoxins,	will	be	required	to	elucidate	clearly	the	relationship	
between	endotoxins	and	radiotherapy-related	enteritis.
This	study	has	a	major	limitation,	which	must	be	considered	
when	interpreting	the	results.	Although	all	12	patients	received	
same	radiation	portal,	i.e.	whole	pelvic	radiotherapy,	with	me-
dian	total	dose	of	50.4	Gy,	the	small	number	of	patients	made	
it	difficult	to	analyze	sufficiently	the	effects	of	changes	in	bio-
logical	markers	on	radiotherapy-related	symptoms.	
Additionally,	we	were	unable	to	effectively	assess	the	effects	
of	the	addition	of	chemotherapy	to	pelvic	radiotherapy	on	the	
outcomes	of	this	study,	although	it	is	known	that	the	addition	
of	chemotherapy	is	one	of	the	most	important	factors	that	
might	influence	treatment-related	complications.	Although	
2	of	3	patients	treated	with	adjuvant	radiotherapy	alone	
without	chemotherapy	showed	significant	changes	in	the	
level	of	endotoxins	during	radiotherapy,	and	these	2	patients	
experienced	nausea	and	vomiting,	it	may	not	be	possible	to	
draw	confirmatory	conclusions	for	the	relationship	between	
the	change	in	the	level	of	endotoxin	and	radiotherapy-related	
adverse	effects.	However,	this	was	a	pilot	study	to	test	the	hy-
pothesis	whether	pelvic	radiotherapy	with	or	without	chemo-
therapy	could	change	some	biologic	markers	that	might	be	
related	with	radiotherapy	and	undoubtedly	showed	that	pel-
vic	radiotherapy	oxidized	the	GSH	redox	system	and	increased	
plasma	endotoxin.
Based	on	these	results,	further	investigations	containing	
interventional	and	longitudinal	studies	will	be	required	to	as-
sess	the	effects	of	the	changes	in	oxidative	stress	markers	and	
endotoxin	on	radiotherapy-related	adverse	events.	Also,	the	
clinical	application	of	these	findings	has	to	be	considered	to	
minimize	radiotherapy-related	adverse	events	and	to	improve	Oxidative stress and plasma endotoxin
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QoL	in	cancer	patients.
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